| scholarly article | Q13442814 |
| P2093 | author name string | J. Crosnier | |
| A. M. Couroucé | |||
| P. Prunet | |||
| P. Jungers | |||
| B. Lacour | |||
| F. Degos | |||
| P. Guesry | |||
| A. Laplanche | |||
| E. Benhamou | |||
| Y. Cerisier | |||
| P2860 | cites work | Virus B hepatitis in hemodialysis centers | Q40802547 |
| Vaccine against hepatitis B--18 months prevention in a high risk setting | Q43873702 | ||
| Hepatitis B vaccine: immune responses in haemodialysis patients | Q72440656 | ||
| Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I, Medical staff | Q72452766 | ||
| P433 | issue | 8224 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis B | Q6853 |
| placebo | Q269829 | ||
| placebo-controlled trial | Q108853737 | ||
| hemodialysis patient | Q126109077 | ||
| P304 | page(s) | 797-800 | |
| P577 | publication date | 1981-04-01 | |
| 1981-04-11 | |||
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in french haemodialysis units: II, Haemodialysis patients | |
| P478 | volume | 1 |
| Q34390072 | 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host |
| Q44266138 | A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report |
| Q35194402 | A review of hepatitis B vaccination |
| Q45840083 | Absence of pre-S2 antibodies in natural hepatitis B virus infection |
| Q44551708 | Active hepatitis B vaccination of dialysis patients and medical staff |
| Q41152617 | CHRONIC HEPATITIS IN PATIENTS OF CHRONIC RENAL FAILURE. |
| Q44145692 | Challenges in containing the burden of hepatitis B infection in dialysis and transplant patients in India |
| Q40461196 | Chronic viral hepatitis and the management of chronic renal failure |
| Q44656357 | Comparison of two plasma-derived hepatitis B vaccines: long-term report of a prospective, randomized trial |
| Q39431239 | Determining the cutoff based on a continuous variable to define two populations with application to vaccines |
| Q43038134 | Efficacy and tolerance of α-2b interferon therapy on HCV infection of hemodialyzed patients |
| Q72567680 | Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff. Double-blind placebo-controlled trial |
| Q70034336 | Efficacy of hepatitis B immunization with reduced intradermal doses |
| Q64381595 | Enhanced immunogenicity of hepatitis B surface antigen by insertion of a helper T cell epitope from tetanus toxoid |
| Q67928080 | Enhancing effects of oral adjuvants on anti-HBs responses induced by hepatitis B vaccine |
| Q45842958 | Epidemiological study of occupational exposure to hepatitis B virus and liver function tests |
| Q45126436 | Epidemiology and risk calculation of hepatitis-B as an occupational disease in the Austrian health service |
| Q51987962 | Erythropoietin enhances immune responses in mice. |
| Q43929599 | Failure of vaccination against hepatitis B with Gen H-B-Vax-D in immunosuppressed heart transplant recipients |
| Q41157904 | GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR IMPROVES IMMUNOGENECITY OF HEPATITIS B VACCINE IN HEMODIALYSIS PATIENTS. |
| Q44545795 | German experimental hepatitis B vaccine--influence of variation of dosage schedule, sex and age differences on immunogenicity in health care workers |
| Q45745542 | Granulocyte-macrophage colony-stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients |
| Q44227059 | HBsAG positive reactivity in man not due to hepatitis B virus |
| Q72819969 | Hepatitis B Vaccination in Down's Syndrome and Other Mentally Retarded Patients |
| Q93614592 | Hepatitis B vaccination and immune response in children with malignant diseases |
| Q68440347 | Hepatitis B vaccination and interleukin 2 receptor expression in chronic renal failure |
| Q50579330 | Hepatitis B vaccination campaign in a low endemicity area. |
| Q24246719 | Hepatitis B vaccination for patients with chronic renal failure |
| Q72190614 | Hepatitis B vaccination of immunosuppressed heart transplant recipients with the vaccine Hepa Gene 3 containing pre-S1, pre-S2, and S gene products |
| Q73710566 | Hepatitis B vaccine in hemodialysis patients with hepatitis C viral infection |
| Q71456322 | Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection |
| Q71945207 | Hepatitis B vaccine in patients on haemodialysis |
| Q72820566 | Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy |
| Q40183746 | Hepatitis B vaccine: further studies in children with previously acquired hepatitis B surface antigenemia |
| Q45828133 | Hepatitis B virus infection and vaccination in children undergoing hemodialysis |
| Q72573925 | Hepatitis B, hepatocellular carcinoma, and strategies for prevention |
| Q42804611 | Hepatitis in dialysis units in the United Kingdom: a Public Health Laboratory Service Survey |
| Q21144733 | Host heterogeneous ribonucleoprotein K (hnRNP K) as a potential target to suppress hepatitis B virus replication |
| Q46046973 | Hydrogel-Delivered GM-CSF Overcomes Nonresponsiveness to Hepatitis B Vaccine through the Recruitment and Activation of Dendritic Cells |
| Q44583099 | Immune response to hepatitis B vaccine in staff and patients in renal dialysis units |
| Q44566626 | Immunogenicity of a hepatitis B subunit vaccine in hemodialysis and in renal transplant recipients |
| Q70272024 | Immunogenicity of hepatitis B vaccine (HEVAC B) in children with advanced renal failure |
| Q69695369 | Immunogenicity of recombinant hepatitis B vaccine in dialysis patients |
| Q36796786 | Impaired immune responses and antigen-specific memory CD4+ T cells in hemodialysis patients |
| Q69551231 | In vivo T cell preactivation in chronic uremic hemodialyzed and non-hemodialyzed patients |
| Q72467501 | Increasing serum creatinine and age reduce the response to hepatitis B vaccine in renal failure patients |
| Q69366949 | Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination |
| Q36555974 | Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease |
| Q35805799 | Perinatal transmission of hepatitis B virus. |
| Q34450177 | Placebos and other comparative treatments |
| Q44563488 | Potential role of soluble CD40 in the humoral immune response impairment of uraemic patients |
| Q33362890 | Potential role of the soluble form of CD40 in deficient immunological function of dialysis patients: new findings of its amelioration using polymethylmethacrylate (PMMA) membrane |
| Q37521846 | Preclinical evaluation of a two-dose vaccination schedule of recombinant Hansenula polymorpha hepatitis B vaccine in animals |
| Q37401961 | Presence of preactivated T cells in hemodialyzed patients: their possible role in altered immunity |
| Q33582879 | Psychosocial impact of chronic infection with hepatitis B virus on British patients |
| Q68428895 | Recombinant gamma-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients |
| Q70326943 | Relationship between liver histopathological changes and HBs Ag in 111 patients treated by long-term hemodialysis |
| Q68011112 | Response to hepatitis B vaccination by liver transplant candidates |
| Q38168296 | Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease |
| Q44745559 | Role for monoclonal hepatitis B antibody in hepatitis B immunisation programmes |
| Q73406638 | Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease |
| Q44315234 | Secondary immune deficiency in renal failure exemplified by hepatitis B vaccination |
| Q35578669 | Selective blockade of the antigen-receptor-mediated pathway of T cell activation in patients with impaired primary immune responses |
| Q44822458 | Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal). |
| Q53740192 | The effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hepatitis B vaccination in haemodialysis patients. |
| Q39520194 | The pre-S region of hepadnavirus envelope proteins |
| Q36115948 | The use of vaccines in renal failure |
| Q43921238 | Thymopentin as adjuvant in non-responders or hyporesponders to hepatitis B vaccination |
| Q45735907 | Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients |
| Q34625147 | Tregs and rethinking cancer immunotherapy |
| Q45861588 | Use of HBV Vaccine in Hemophiliacs |
| Q71618477 | Use of immunoglobulin with high content of antibody to hepatitis B surface antigen (anti-HBs). Working Party on the Clinical Use of Specific Immunoglobulin in Hepatitis B |
| Q40807088 | Use of the hepatitis B recombinant DNA yeast vaccine (H-B-VAX II) in children: two doses vs. three doses of 5 micrograms regime; an interim report |
| Q43434094 | Vaccination of patients with liver disease: who, when, and how. |
| Q69920966 | Viral hepatitis B. Risk for the anesthetist |
| Q37275962 | Viral hepatitis in elderly haemodialysis patients: current prevention and management strategies. |
| Q81710244 | [Chronic hepatitis B: unusual situations: dialysis, renal transplantation and pre-emptive therapy in immune compromised patients] |
| Q93137235 | [Nobel prize and the history of blood transfusion] |
Search more.